News from cyxone A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 20, 2020, 03:36 ET Dr Tara Heitner Appointed New CEO for Cyxone

Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that Tara Heitner PhD MBA has been appointed new CEO for the company by...


Jan 29, 2020, 05:58 ET Cyxone Orders More Rabeximod Substance and Confirms Timeline for the Phase IIb Program

Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that an order of more Rabeximod substance will be placed earlier than...


Nov 21, 2019, 07:53 ET Cyxone Signs a UK Contract Research Organization for Six-month Toxicology Studies With Rabeximod

Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company has signed an agreement with a UK contract research...


Nov 13, 2019, 11:59 ET Kjell G. Stenberg Steps Down as CEO of Cyxone

Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company's Board has resolved to find a new CEO to lead the company...


Sep 04, 2019, 08:53 ET Cyxone Explores Orphan Drug Designation for Rabeximod

Cyxone (publ), a Swedish biotechnology company in autoimmune diseases, today announced that the company's board of directors has decided to explore...


Aug 29, 2019, 06:17 ET Cyxone's CEO Kjell G. Stenberg Acquires Additional Shares in the Company

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company's CEO Kjell G. Stenberg has for private account increased...


Aug 02, 2019, 04:42 ET Cyxone's T20K Shows Favorable Safety and Tolerability in First-in-human Trial

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the clinical phase I trial with drug candidate T20K successfully...


Jul 19, 2019, 02:38 ET Cyxone Makes Further Strides With Rabeximod Phase IIb Trial by Signing CRO EGeen Inc.

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company has signed an agreement with EGeen Inc., a clinical...


Jul 12, 2019, 04:28 ET Cyxone Announce Dosing of First Volunteer in T20K's First-in-human Trial

Cyxone (publ.) a Swedish biotech in autoimmune diseases, today announced that the first healthy male volunteer has received the initial dose in its...


Jul 05, 2019, 03:31 ET Cyxone Submits First Application to Start Clinical Phase IIb Trial With Rabeximod

Cyxone (publ), a Swedish biotech in autoimmune diseases, today submitted an application to the Central Ethics Committee (CEC) in Poland for...


Jul 01, 2019, 12:09 ET First Berlin Equity Research Publishes Updated Independent Analysis of Cyxone

Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent...


Jun 20, 2019, 06:49 ET Cyxone Initiates First-in-human Trial With T20K for the Treatment of MS

Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company starts its first-in-human, phase I, clinical trial with...


May 23, 2019, 10:21 ET Cyxone Submits Application to Start First-in-human Trial With T20K in MS

Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company has set a date for the application submission for the...


Mar 20, 2019, 05:32 ET Cyxone Announces Strategic Intent to Position its Drug Candidate T20K in MS as a Prophylactic Agent

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that preclinical findings support the positioning of its drug candidate T20K ...


Feb 04, 2019, 04:36 ET Cyxone Announces Issuance of U.S. Divisional Patent for Drug Candidate T20K in MS

Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent...


Dec 03, 2018, 11:42 ET First Berlin Equity Research Publishes Updated Independent Analysis of Cyxone

Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent...


Nov 28, 2018, 03:00 ET Cyxone Concludes T20K's Preclinical Program Following Positive Results in Toxicology Studies

Cyxone (publ) announced today that the preclinical program for drug candidate T20K in multiple sclerosis (MS) has been concluded following positive...


Oct 31, 2018, 03:42 ET First Berlin Equity Research Publishes Independent Analysis of Cyxone

Cyxone (publ) announced today that the internationally renowned research house First Berlin Equity Research has published an independent analysis...


Oct 23, 2018, 02:34 ET Cyxone Selects First Clinical Site Ahead of Phase 1 Study With T20K in MS

Cyxone AB (publ) announced today that the company has selected the clinical site that will carry out the drug candidate T20K's first in man study....


Jun 01, 2018, 09:44 ET Cyxone Completes Acquisition of Drug Candidate Rabeximod

Cyxone AB (publ) announced today that the company has decided to complete the acquisition of drug candidate Rabeximod and issue approximately 1.9...


Mar 27, 2018, 08:50 ET Cyxone's Cyclotide Shows Promising Interim Results in IBD Pilot Study

Cyxone announced today that the first phase of their cyclotide pilot study into inflammatory bowel disease (IBD) has been concluded as planned. The...